

## Special Issue

# The 50th Anniversary of the Discovery of the First Statin by Prof. Dr. Akira Endo: Lipid-Lowering Drugs and Strategies

### Message from the Guest Editors

The rate-controlling enzyme of cholesterol synthesis is 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase). In the midsummer of 1972, Dr. Akira Endo and his team discovered that the mold *Penicillium citrinum*, which was isolated from a rice sample collected at a grain shop in Kyoto, inhibited HMG-CoA reductase. In July 1973, they isolated three active metabolites from the culture broth and the most active product of these three was named ML-236B, also known as compactin or mevastatin. This discovery led to the development of statins as hypolipidemic drugs, resulting in the demonstration of the efficacy of statins in multiple primary and secondary prevention trials. To celebrate the 50th anniversary of Dr. Akira Endo's truly unique and historic contribution to science and medicine, this commemorative Special Issue focuses on lipid-lowering drugs and strategies, including biological drug products.

### Guest Editors

Prof. Dr. Bart De Geest

Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Campus Gasthuisberg, Herestraat 49 bus 911, 3000 Leuven, Belgium

Dr. Takayuki Masaki

Department of Endocrinology and Metabolism, Faculty of Medicine, Oita University, Oita, Japan

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/128158](https://mdpi.com/si/128158)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).